Decheng Capital LLC bought a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,285,293 shares of the company's stock, valued at approximately $54,010,000. Upstream Bio comprises about 11.6% of Decheng Capital LLC's investment portfolio, making the stock its 3rd largest position. Decheng Capital LLC owned approximately 6.13% of Upstream Bio as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in UPB. Moody Aldrich Partners LLC acquired a new stake in Upstream Bio in the fourth quarter worth about $1,229,000. Rhumbline Advisers acquired a new position in shares of Upstream Bio during the fourth quarter valued at approximately $275,000. Bank of New York Mellon Corp bought a new stake in Upstream Bio during the fourth quarter worth approximately $607,000. US Bancorp DE bought a new position in Upstream Bio during the 4th quarter valued at $27,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Upstream Bio during the 4th quarter valued at $2,225,000.
Upstream Bio Price Performance
NASDAQ:UPB traded up $0.28 during mid-day trading on Wednesday, reaching $9.26. 189,688 shares of the stock were exchanged, compared to its average volume of 263,788. Upstream Bio, Inc. has a 1-year low of $5.14 and a 1-year high of $29.46. The business has a fifty day moving average price of $7.90 and a 200 day moving average price of $14.37.
Upstream Bio Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
